Can a month of pills boost radiation for prostate cancer?

NCT ID NCT06111781

Recruiting now Disease control Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 22, 2026 · Updated 3 times

Summary

This study tests whether adding a short, 30-day course of the oral hormone drug Relugolix to standard targeted radiation (SBRT) works better than radiation alone for men with intermediate-risk prostate cancer. About 60 men will be randomly assigned to one of the two treatments. The main goal is to see if the combination leads to a lower PSA level after treatment, while also tracking side effects and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Relugolix (Orgovyx) and stereotactic body radiotherapy (SBRT)
What this could lead to: If successful, this could show that a short 30-day course of Relugolix plus SBRT controls prostate cancer better than SBRT alone, with fewer side effects than longer hormone therapy.
What could go wrong: This is a small Phase 2 trial with only 60 participants, so results may not apply to all patients. The short hormone course might not be enough to improve outcomes, and side effects from Relugolix or SBRT are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Dartmouth-Hitchcock Medical Center
NOT_YET_RECRUITING

Lebanon, New Hampshire, 03756, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10017, United States
University of Washington
RECRUITING

Seattle, Washington, 98109, United States
Yale Cancer Center
RECRUITING

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.